RhumbLine Advisers
KROS icon

RhumbLine Advisers’s Keros Therapeutics KROS Stock Holding History

RhumbLine Advisers’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Sell
32,755
-7,421
-18% -$82.7K ﹤0.01% 2976
2026
Q1 		$444K Sell
40,176
-4,059
-9% -$62.7K ﹤0.01% 2689
2025
Q4 		$901K Sell
44,235
-6,243
-12% -$110K ﹤0.01% 2293
2025
Q3 		$799K Sell
50,478
-1,337
-3% -$19.8K ﹤0.01% 2382
2025
Q2 		$692K Buy
51,815
+7,146
+16% +$96.5K ﹤0.01% 2453
2025
Q1 		$455K Buy
44,669
+3,802
+9% +$44.1K ﹤0.01% 2637
2024
Q4 		$647K Buy
40,867
+391
+1% +$20.3K ﹤0.01% 2500
2024
Q3 		$2.35M Sell
40,476
-1,162
-3% -$57.4K ﹤0.01% 1816
2024
Q2 		$1.9M Buy
41,638
+7,111
+21% +$382K ﹤0.01% 1914
2024
Q1 		$2.29M Buy
34,527
+2,870
+9% +$170K ﹤0.01% 1839
2023
Q4 		$1.26M Sell
31,657
-886
-3% -$27.8K ﹤0.01% 2144
2023
Q3 		$1.04M Sell
32,543
-410
-1% -$15.3K ﹤0.01% 2188
2023
Q2 		$1.32M Buy
32,953
+4,862
+17% +$213K ﹤0.01% 2148
2023
Q1 		$1.2M Buy
28,091
+1,707
+6% +$86.2K ﹤0.01% 2044
2022
Q4 		$1.27M Buy
26,384
+3,027
+13% +$141K ﹤0.01% 2021
2022
Q3 		$879K Buy
23,357
+3,106
+15% +$108K ﹤0.01% 2204
2022
Q2 		$560K Buy
20,251
+4,365
+27% +$192K ﹤0.01% 2442
2022
Q1 		$864K Buy
15,886
+1,984
+14% +$102K ﹤0.01% 2189
2021
Q4 		$813K Sell
13,902
-283
-2% -$14.1K ﹤0.01% 2295
2021
Q3 		$561K Buy
14,185
+680
+5% +$24.2K ﹤0.01% 2494
2021
Q2 		$574K Sell
13,505
-170
-1% -$9.21K ﹤0.01% 2505
2021
Q1 		$842K Buy
13,675
+64
+0.5% +$4.05K ﹤0.01% 2267
2020
Q4 		$960K Buy
13,611
+6,588
+94% +$415K ﹤0.01% 2149
2020
Q3 		$271K Sell
7,023
-811
-10% -$32.2K ﹤0.01% 2560
2020
Q2 		$294K Buy
+7,834
New +$241K ﹤0.01% 2587

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

RhumbLine Advisers's KROS Position: Q2 2026 in Review

RhumbLine Advisers reduced its Keros Therapeutics (KROS) stake by 18% in Q2 2026, selling an estimated $82.7K and leaving 32,755 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #2976.

RhumbLine Advisers first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.35M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • RhumbLine Advisers held 32,755 shares of Keros Therapeutics worth $350K as of Q2 2026.
  • RhumbLine Advisers sold 7,421 Keros Therapeutics shares in Q2 2026, an estimated $82.7K.
  • Keros Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2976 holding.
  • RhumbLine Advisers first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • RhumbLine Advisers's Keros Therapeutics position peaked at $2.35M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.